Blood biomarker panel separates Alzheimer disease from healthy controls in a single-center analysis
A blood-based biomarker panel combining neurotrophic factors, tau species, neuronal injury markers and peripheral inflammatory indices distinguished Alzheimer disease from healthy controls with striking internal accuracy in a single-center nested cross-validation study. The design matters because the analysis did not rely on a single marker behaving well in isolation; it tested whether a multi-pathway signature could better capture the biological spread of the disease than univariate screening ever could.
The cohort included 200 participants, evenly divided between 100 people with Alzheimer disease and 100 healthy controls. Investigators measured 12 blood biomarkers spanning several mechanistic domains: neurotrophic factors, tau proteins, markers of neuronal injury and peripheral inflammatory indices. In practice, that kind of panel aims to read the disease from several angles at once — synaptic support, axonal damage, tau-related pathology and systemic immune perturbation — rather than asking one molecule to carry all the diagnostic weight.
A brief result stands out immediately. The model barely missed anything within the internal cross-validation framework.
Tau and axonal injury markers carried the most consistent signal
Exploratory analyses used principal component analysis and orthogonal partial least squares discriminant analysis to visualize group separation before the more formal selection pipelines were applied. Nested stratified ten-fold cross-validation was built into the workflow to reduce data leakage, a critical safeguard in a small biomarker study where optimistic performance can appear the moment training and testing data blur together. Feature selection then leaned on L1-penalized LASSO logistic regression as the primary approach, with a stacking ensemble model used for benchmarking.
Under the lambda.1se criterion, eight predictive biomarkers remained in the final LASSO model. Among them, BDNF, NGF, NFL and pTau217 were selected consistently by both analytical pipelines. A second tier of stable markers included pTau231 and S100β. The consistency of the core Alzheimer-related markers across two different modeling strategies is clinically important, because reproducibility matters more than a momentary spike in fit statistics when a biomarker is meant to serve as a diagnostic aid.
The biological logic is coherent. Tau phosphorylation reflects the evolving burden of Alzheimer neuropathology, while neurofilament light chain tracks axonal injury and neurotrophic factors such as BDNF and NGF speak to neuronal maintenance and repair capacity. When those signals move in the same diagnostic direction, they suggest a disease state that is not defined by one lesion class alone but by a layered process involving neuronal stress, structural injury and reduced trophic support.
Peripheral inflammatory markers were less stable than core Alzheimer signals
The inflammatory measures were less reliable. PLR and SII were excluded by LASSO-1se but appeared intermittently in the stacking model, while Lym survived only in the LASSO-1se analysis. Age, gender, neutrophil count and platelet count were eliminated in both models. In other words, generic systemic blood features did not compete well with the disease-linked markers that sit closer to the central nervous system pathology.
That pattern fits the underlying biology. Peripheral inflammation may accompany Alzheimer disease, but it is not specific enough to anchor a diagnostic classifier on its own. A blood count can reflect infection, stress, medications or a host of non-neurologic states. By contrast, tau-related markers and neurofilament light chain are more tightly connected to the neurodegenerative process itself, which helps explain why they remained durable when the models were pared down.
Internal performance was almost perfect, but the study stops short of clinical use
The LASSO-derived model produced an out-of-fold AUROC of 0.9999 and an AUPRC of 0.9999. The stacking model performed almost identically, with AUROC of 0.999 and AUPRC of 0.999. Those numbers are remarkable, but they are also bounded by the environment in which they were generated: single-center internal cross-validation with no external validation cohorts. A model can look extraordinary when the same institutional setting shapes recruitment, sample handling and assay context for every observation.
External multi-cohort validation remains mandatory before any clinical application. Without it, the panel cannot be assumed to generalize across hospitals, assay platforms, ethnic backgrounds, disease stages or the messier diagnostic mixes that characterize routine memory clinics. The study does, however, provide a strong proof of concept that a small blood panel may capture several of the molecular threads running through Alzheimer disease at once.
One practical implication is straightforward. If future cohorts reproduce these results, a blood test built around pTau217, pTau231, NFL, BDNF, NGF and related markers could support earlier triage of patients who need more definitive neurologic workup. That would not replace clinical assessment or established imaging and cerebrospinal fluid tools, but it could reduce the delay between first cognitive symptoms and a biologically informed diagnosis.
A multimodal panel reflects several disease pathways at once
The most useful aspect of this study is not the perfect classification score. It is the way the panel maps onto Alzheimer biology. Tau pathology, axonal injury, neurotrophic deficiency and peripheral immune perturbation are not isolated events; they move through overlapping networks that shape symptom onset and progression. A model that can detect multiple components of that process in blood is attractive because it may be closer to how the disease behaves in real patients than a single-marker assay ever could be.
Still, the present findings remain an internal demonstration rather than a deployable clinical test. The study used a single center, a relatively small sample and only healthy controls for comparison. That leaves several practical questions unanswered: how the panel performs against other dementias, how it behaves in prodromal disease, and whether assay drift or broader population diversity will weaken its accuracy once the setting moves beyond one institution.
For now, the study shows that a carefully constructed blood biomarker strategy can separate Alzheimer disease from healthy control samples with extraordinary internal discrimination. The next step is not refinement of the training curves. It is whether the same signal survives contact with independent patients, independent laboratories and the diagnostic ambiguity of everyday neurology.